{"url_path":"/sec/ntla/8-k/2026-04-27/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1652130/0001193125-26-179401-index.html","accession_number":"0001193125-26-179401","cik":"0001652130","ticker":"NTLA","issuer_name":"Intellia Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1652130/0001193125-26-179401-index.html","primary_entity_key":"0001652130","primary_entity_name":"Intellia Therapeutics, Inc."},"word_count":118,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\nNo.\n  \n\nDescription\n\n99.1\n  \n[Press Release dated April 27, 2026 titled “Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing”](d138980dex991.htm)\n\n99.2\n  \n[Presentation dated April 2026 titled “Phase 3 HAELO Clinical Trial: Topline Data for Lonvo-z”](d138980dex992.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \nIntellia Therapeutics, Inc.\n\nDate: April 27, 2026\n \n\n \nBy:\n \n\n/s/ John M. Leonard\n\n \n\n \nName:\n \nJohn M. Leonard\n\n \n\n \nTitle:\n \nChief Executive Officer and President"}